New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer's disease

BioArctic’s (via Eisai) Leqembi (lecanemab) presented new 2026 AAIC data in London, focused on subcutaneous administration. The article provides no quantified efficacy/safety results, so the near-term read-through is mildly positive for product development/expansion prospects, but likely limited immediate stock impact.

Analysis

BioArctic’s (via Eisai) Leqembi (lecanemab) presented new 2026 AAIC data in London, focused on subcutaneous administration. The article provides no quantified efficacy/safety results, so the near-term read-through is mildly positive for product development/expansion prospects, but likely limited immediate stock impact.